Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor mutation burden (TMB), a promising …
A newly published study of older adults residing in assisted living and independent living communities shows significant improvement in brain processing speed among those who used a …
Zynerba Pharmaceuticals on Thursday announced negative topline results from a Phase 1 safety and dosing study of its transdermal tetrahydrocannabinol patch ZYN001, sending shares down …
Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met its primary objective, showing a …
AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …
Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data after 36 weeks. The study …
Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children with Debilitating, Lifelong Hereditary Disease Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Kyowa …
Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq Copenhagen: GEN) announced today that …
Data from the study will be submitted to the FDA in support of Market Clearance for TIGERTRIEVER in the U.S. Rapid Medical, an Israeli company …
Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
